0 Items
Select Page

Epstein Barr Virus

The Epstein–Barr virus (EBV) is one of the most commonly found viruses in humans and is best known for causing infectious mononucleosis (glandular fever). EBV is also associated with particular forms of cancer, including Hodgkin’s lymphoma, Burkitt’s lymphoma, gastric cancer and nasopharyngeal carcinoma. About 200,000 cancer cases per year are thought to be attributable to EBV.

The Native Antigen Company have developed recombinant antigens for use in EBV research and assay development.

Epstein Barr Virus Background

Epstein Barr Virus (EBV) is a double-stranded DNA, enveloped virus, with a large genome encoding 200 proteins. Epstein Barr virus, also known as Herpes virus 4 (HHV4), belongs to the gammaherpesvirinae subgroup of the Herpesvirus family.

EBV is widely distributed and is estimated to affect around 90% of the human population. In developing countries, most children contract EBV infection at an early age. In developed countries, primary EBV infection is more common in adolescents and adults. The Epstein-Barr virus is commonly spread from human-to-human through saliva and other body fluids (CDC).

In most cases, EBV Infection is asymptomatic, but some individuals develop infectious mononucleosis, a condition that is generally self-limiting but can cause prolonged fatigue lasting for several months. After primary EBV infection, the virus remains latent and can re-activate under certain circumstances. In immunocompromised patients, EBV infection is associated with various malignancies, autoimmune disease and other chronic and acute illnesses.

Epstein-Barr virus primarily targets B-lymphocytes but is also reported to infect epithelial cells, T-cells, natural killer cells, smooth muscle cells and monocytes (Hutt-Fletcher, L.M.).

Epstein Barr Virus Antigens

The Native Antigen Company has developed and produces recombinant Epstein Barr Virus gp125 antigens using our proprietary mammalian expression system. These antigens are suitable for research and development into Epstein-Barr virus biology and in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 15 =

Live Customer Feedback

Join our mailing list

* indicates required